Anti-Epidermal Growth Factor Receptor (EGFR) antibodies can competitively bind to EGFR, reducing the secretion of immunosuppressive cytokines by tumor cells [85] (such as vascular endothelial growth factor, IL-10). This evidence concerns the gene EGFR and neoplasm.